Egis reported third fiscal quarter figures in line. IFRS consolidated net income came in at HUF 4.37bn, up 104.0% y/y and up 20.4% q/q. The figure was broadly in line with consensus forecast of HUF 4.42bn (three forecasts obtained by Reuters ranged between HUF 4.21–4.79bn) and almost fully matches our own estimate of HUF 4.38bn. 9M cumulated net earnings of 14.4bn stands at 92.3% of FY06/05 net profit estimate available on Bloomberg. Non-consolidated IFRS net profit of HUF 3.99bn, however, beat market consenus of HUF 3.67bn. Although the result didn’t contain any major surprises for us, we would highlight that export-driven top line growth (+30% y/y if adjusting to the dilutive drug wholesale business) and bottom line growth (+102% y/y) hit CEE competitors by far.